tDCS for Parkinson's (NCT05919485)
Improve thinking with brain stimulation
- Trial ID
- NCT05919485
- Official Title
- The Effects of Specific Transcranial Direct Current Stimulation tDCS on Cognition in Mild Cognitive Impairment: A Novel Study Protocol
- Goal
- Improve thinking with brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Istanbul Medipol University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 120 participants
- Conditions
- Alzheimer Disease, Parkinson Disease
- Interventions
- tDCS
Summary For Families
The goal is to see whether gentle, noninvasive electrical stimulation of the scalp can improve memory and other thinking skills in people with mild cognitive impairment related to Parkinson's or early Alzheimer's. The approach uses transcranial direct current stimulation, a very low, painless current applied to targeted brain regions to boost neuronal activity involved in memory and attention, and it is given alongside participants' regular medications rather than replacing levodopa or other drugs. They are enrolling 120 literate adults aged 45 to 80, balanced by sex, who have Parkinson's with mild cognitive impairment or amnestic MCI, are on stable medications for at least one month, and who do not have dementia, major medical or other neurologic/psychiatric conditions, or any contraindication to tDCS or fMRI.
Locations
- Alanya Alaaddin Keykubat Üniversitesi, Antalya, Alanya, Turkey (Türkiye)
Frequently Asked Questions
- What is this trial testing?
- This trial is studying tDCS. The goal is to see whether gentle, noninvasive electrical stimulation of the scalp can improve memory and other thinking skills in people with mild cognitive impairment related to Parkinson's or early Alzheimer's. The approach uses transcranial direct current stimulation, a very low, painless current applied to targeted brain regions to boost neuronal activity involved in memory and attention, and it is given alongside participants' regular medications rather than replacing levodopa or other drugs. They are enrolling 120 literate adults aged 45 to 80, balanced by sex, who have Parkinson's with mild cognitive impairment or amnestic MCI, are on stable medications for at least one month, and who do not have dementia, major medical or other neurologic/psychiatric conditions, or any contraindication to tDCS or fMRI.
- Who can participate?
- Participants must be between 45 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 5 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This trial has 3 groups, and 1 is a sham (a pretend version of the procedure) group. Because assignment is random, you have about a 1 in 3 chance (roughly 33%) of being in the sham group, assuming the groups are filled equally. Ask the coordinator to confirm the exact assignment ratio.
- How many visits does this trial involve?
- There is a baseline neurocognitive evaluation done before atDCS; the atDCS treatment consists of a total of 10 sessions in 14 days (20 minutes a day, 5 days a week); evaluations are repeated at the end of 14 days and at 90 days.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: MRI scan (non-invasive); Brain wave recording (EEG) (non-invasive). Confirm the full schedule with the study coordinator.
- Is there a medication washout in this trial?
- Participants must be on a stable pharmacological treatment for a minimum of one month with no washout period.